Log in to search using one of your social media accounts:

 

Antibody Appears to Attack Cancer Cells, Leaving Other Cells Unscathed

Contact: Sarah Avery Phone: 919-660-1306 Email: sarah.avery@duke.edu https://www.dukehealth.org EMBARGOED FOR RELEASE until 12 p.m. noon (ET) on Thursday, May 5, 2016 DURHAM, N.C. -- A research team from Duke Health has developed an antibody from the body’s own immune system that preferentially attacks cancer cells. The antibody works by targeting a natural defense mechanism that cancer tumors exploit. Cells in the body essentially use a home security system that relies on certain proteins to protect the cell surface and keep it safe. These proteins help the cell avoid injury and even death from unwanted activation of the immune system. In a paper published online May 5 in Cell Reports, the Duke team describes the workings of a cancer-fighting antibody they discovered, developed and tested in cell lines and animal models. The antibody dismantles a specific part of a cancer cell’s defense system and then employs several mechanisms of attack. "This is the first completely human-derived antibody developed as an anti-cancer therapy, which is very different from other immunotherapy approaches,” said senior author Edward F. Patz, Jr., M.D., the James and Alice Chen Professor of Radiology and professor in the Department of Pharmacology and Cancer Biology at Duke. Patz and colleagues -- including principals from the Duke Human Vaccine Institute who have been advancing the development of antibodies for an HIV vaccine -- started with the observation that some lun...
Source: DukeHealth.org: Duke Health Features - Category: Pediatrics Tags: Duke Medicine Source Type: news

Related Links:

Free‑floating cancer cells in lymph node sinuses of hilar lymph node‑positive patients with non‑small cell lung cancer. Mol Med Rep. 2018 May 14;: Authors: Nakamura Y, Mukai M, Hiraiwa S, Kishima K, Sugiyama T, Tajiri T, Yamada S, Iwazaki M Abstract Previous studies demonstrated that free‑floating cancer cells (FFCCs) in the lymph node sinuses were of prognostic significance for colorectal and gastric cancer. The present study investigated the clinical significance of detecting FFCCs using Fast Red staining for cytokeratin in stage I/II non‑small cell lung cancer (NSCLC) patients and hil...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Abstract As a potent chemotherapy drug, cisplatin is also notorious for its side effects including nephrotoxicity in kidneys, presenting a pressing need to identify renoprotective agents. Cisplatin nephrotoxicity involves epigenetic regulations, including changes in histone acetylation. Bromodomain and extra-terminal (BET) proteins are "readers" of the epigenetic code of histone acetylation. Here, we investigated the potential renoprotective effects of JQ1, a small molecule inhibitor of BET proteins. We show that JQ1 significantly ameliorated cisplatin-induced nephrotoxicity in mice as indicated by the m...
Source: Am J Physiol Renal P... - Category: Urology & Nephrology Authors: Tags: Am J Physiol Renal Physiol Source Type: research
Abstract BACKGROUND AND AIMS: Increasing evidence has shown the critical role of long non-coding RNA cytoskeleton regulator (CYTOR) in cancers. The expression of CYTOR is reported to be up-regulated in many kinds of cancers, such as gastric cancer, hepatocellular carcinoma, colon cancer, lung adenocarcinoma, oesophageal squamous cell carcinoma and renal cell carcinoma. Here, we summarized related studies and performed a meta-analysis to investigate the prognostic value of CYTOR in multiple cancers. METHODS: Eligible studies were retrieved from PubMed, Embase and Cochrane Library databases, and the role of CYT...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Clin Chim Acta Source Type: research
CONCLUSIONS: Numerous studies have indicated that lncRNA PVT1 will most likely become a novel target for cancer therapy with the deepening systematic research. PMID: 29739059 [PubMed - in process]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Clin Lab Source Type: research
The National Cancer Institute,Laboratory of Molecular Biologyseeks parties interested in collaborative research to further co-develop monoclonal antibodies for the treatment of mesothelin-expressing cancers. The antibody was able to inhibit tumor growth in mouse xenograft models, and corresponding immunotoxins were able to inhibit tumor cell growth in vitroMesothelin is a cell surface protein that is highly expressed in aggressive cancers such as malignant mesothelioma, ovarian cancer, pancreatic cancer, lung cancer, breast cancer, cholangiocarcinoma, bile duct carcinoma and gastric cancer. This selective expression makes ...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
In conclusion, miR-223/FBXW7 axis regulates doxorubicin sensitivity through EMT in CRC, which may lead to the development of individualized treatment in clinical practice. PMID: 29701752 [PubMed - as supplied by publisher]
Source: Acta Biochimica et Biophysica Sinica - Category: Biochemistry Authors: Tags: Acta Biochim Biophys Sin (Shanghai) Source Type: research
Authors: Dranitsaris G, Zhu X, Adunlin G, Vincent MD Abstract INTRODUCTION: After years of setback, cancer immunotherapy has begun to yield clinical dividends, which are changing the treatment landscape and offering cancer patients the potential for long-term survival, reduced treatment-related toxicity and improved quality-of-life. Using the immune system to treat cancer is known as 'Immuno-oncology' (IO) and agents are sub-classified by their ability to enhance anti-tumor response or to direct the immune system to attack cancer cells via tumor-associated antigens. Areas covered: Clinical trials have demonstrated ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
Abstract Gastric cancer is the fifth most common malignancy all over the world, and the factors that can affect progress and prognosis of the gastric cancer patients are various, such as TNM stages, invasive depth, and lymph node metastasis ratio. T cell immunity is important component of human immunity system and immunity responding to tumor and dysfunction or imbalance of T cell immunity will lead to serious outcomes for body. T cell immunity includes many different types of cells, CD4+ T cell, CD8+ T cell, memory cell, and so on, and each of them has special function on antitumor response or tumor immune escape...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
CONCLUSIONS: Long non-coding RNAs-DANCR likely serves as a useful disease biomarker or therapeutic cancer target. PMID: 29728310 [PubMed - as supplied by publisher]
Source: Pathology, Research and Practice - Category: Pathology Authors: Tags: Pathol Res Pract Source Type: research
Objective: To assess the effect of the medical consortium policy on the outcomes of cancer patients admitted to secondary hospitals in Shanxi, China.Method: Electronic medical records of lung cancer (n = 8,193), stomach cancer (n = 5,693) and esophagus cancer (n = 2,802) patients hospitalized in secondary hospitals were used. Propensity score matching was used to match each patient enrolled in medical consortium hospitals with a counterpart admitted in nonmedical consortium hospitals. Cox proportional hazard models were used to estimate the hazard ratio of patients enrolled different categories of hospitals.Results: The ha...
Source: International Journal of Integrated Care - Category: Nursing Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Cancer Therapy | Cancer Vaccines | Drugs & Pharmacology | Funding | Gastric (Stomach) Cancer | Gastroenterology | Genetics | Health | Immunotherapy | Lung Cancer | National Institutes of Health (NIH) | Pediatrics | Radiology | Study | Vaccines | Veterinary Vaccinations